Everyone in CRIS needs to have patients, by EOY we should be @ $3.00 and 2017 will be fine. Relax!
for what it's worth a small brokerage outfit, Suntrust, placed a buy on Curis with a target of $3, the price where Curis was on the day before last Christmas. $3 sure seems like a long way off now, but hopefully we have at least bottomed out. I see CEO took a haircut on compensation in 2016.
how does Curis stay afloat? second offering towards the end of 2016. a few catalysts between now and then that may bring the share price up and prevent some really total dilution. a lot can happen in a year. or with cris absolutely nothing can happen in a year.
Since I have hedged my bet on FDA's approval of 907 and since PH2 has a 12 to 15 month enrollment period, how does Curis stay afloat when it appears, if all goes according to plan, the earliest FDA would approve the drug for commercial use would be after CRIS runs out of its existing cash in late 2017.
I'm totally blown away. A few guys were bragging about their winnings on the yahoo message boards, so I decided to go to the 'Penny Stock 101' website (just google or yahoo search for it) and signed up to their email newsletter. (There is no charge to become a member) Their last 6 winners in this Winter season ran for +33%, +45%, +58%, +64% +72%, and +116% gains. Do yourself a favor and get to that website right now, and become a member. I guarantee u will thank me later.
At end of 2016 if that is all Curis has left, that will not be enough to fund the ongoing CUDC 907 trials in 2017; only hope I can see is that results of PH2 trial show enough promise by end of the year to give Curis leverage to extract capital from a hedge fund or another issuance. What does First Eagle do in this situation? I assume they are stuck with their position as too many shares to cash out.
I'm still in but I can't blame you, Curis has been very painful to me. I'm going to hold until it gets to the 2s again and probably do the same, sell at a loss..
Unfortunately I made the decision to sell out today. 4 painful years with some small trading during it-but not my core. Based on Ali's lack of leadership (imo); the cash burn and where they need to go yet; the fact that last year the same day they had their Feb. CC they diluted AH(and they do need a lot more money to move forward); and where I perceive the broader markets are going in the next year or more, it was time. Again good luck to all.
Sentiment: Strong Sell
He's taking us to victory with incredible CASH BURN!!!! When I get a chance I'll chronicle his achievements since joining the co. beginning with being involved in the decision process to jack the 427 dosage to get us a clinical hold.
Curis appears to be in desperate need of money; report hints of a possible collaborator in 2016. At least CEO will keep presenting at upcoming conferences. Has a patient yet to be dosed in the 907 Ph2 trial?